Annals of Oncology Advance Access originally published online on December 15, 2005
Annals of Oncology 2006 17(3):415-423; doi:10.1093/annonc/mdj108
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects
1 Institute of Medical Psychology, 2 Transplant Center and 3 Clinic and Policlinic for Radiotherapy and Radiooncology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany; 4 Department of Gynecology and Obstetrics, Ulm University Clinic, Ulm, Germany; 5 Department of Hematology and Oncology, Oldenburg Community Hospital, Oldenburg, Germany; 6 Department of Hematology, Oncology, and Transfusion Medicine, Berlin University Clinic Benjamin Franklin, Berlin, Germany
* Correspondence to: A. Scherwath, Center for Psychosocial Medicine, Institute of Medical Psychology, Hamburg-Eppendorf University Medical Center, Martinistrasse 52 (S35), 20246 Hamburg, Germany. Tel: +49-40-42803-7565; Fax: +49-40-42803-4940; E-mail: a.scherwath{at}uke.uni-hamburg.de
Background: Studies on cognitive functioning in breast cancer patients point out that a subset of women exhibit chemotherapy-related neuropsychological impairment. Thereby, high-dose therapy may elevate the risk of cognitive dysfunctions. The primary purpose of the study was to evaluate the impact of high-dose versus standard-dose chemotherapy on the late neuropsychological outcome in randomized assigned high-risk breast cancer survivors. Next to focusing prevalence, function specificity and extent of cognitive impairment, the question as to whether doses-dependant group differences occur was investigated.
Patients and methods: Twenty-four high-dose and 23 standard-dose patients 5 years, on average, after treatment underwent a comprehensive neuropsychological assessment. In addition, 29 early-stage breast cancer patients matched for age, education and time since treatment were recruited as a comparison group.
Results: Global cognitive impairment was observed in 8% of high-dose versus 13% of standard-dose compared with 3% of early-stage breast cancer patients. Compared with normative data, all patient groups performed worse on one attention subtest measuring the simple reaction time (P < 0.001 in each case). By contrast, no significant between-group differences on the late neuropsychological outcome were found.
Conclusions: Five years after treatment, standard-dose patients were slightly, but not significantly, more impaired in cognitive performance than high-dose patients.
Key words: breast cancer, cognitive function, high-dose chemotherapy, long-term treatment effects, neuropsychological outcome
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Vardy, J. S. Wefel, T. Ahles, I. F. Tannock, and S. B. Schagen Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop Ann. Onc., April 1, 2008; 19(4): 623 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Vardy, S. Rourke, and I. F. Tannock Evaluation of Cognitive Function Associated With Chemotherapy: A Review of Published Studies and Recommendations for Future Research J. Clin. Oncol., June 10, 2007; 25(17): 2455 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Altundag, C. Moussallem, and M. Baptista Promotion of neurogenesis by human stem cells in high-risk breast cancer survivals after stem-cell supported high-dose therapy Ann. Onc., September 1, 2006; 17(9): 1465 - 1465. [Full Text] [PDF]
|
|
|
|
|
|
A Scherwath Reply to 'Promotion of neurogenesis by human stem cells in high-risk breast cancer survivals after stem-cell supported high-dose therapy' by K. Altundag et al. (Ann Oncol 2006; 17: 1465) Ann. Onc., September 1, 2006; 17(9): 1465 - 1466. [Full Text] [PDF]
|
|